Intriguingly, there is no current evidence that SGLT2 channels are expressed in cardiac tissue (5), and recent work has demonstrated that genetic knockout of the SGLT2 channel in mice is not sufficient to reproduce the amelioration in heart failure with reduced ejection fraction (HFrEF) that is seen with empagliflozin treatment (6). This evidence concerns the gene SLC5A2 and heart failure.